Anti-inflammatory Therapy Before Reperfusion Therapy in Patients with Ischemic Vascular Disease on the Incidence of Ischemic Reperfusion Injury: An Evidence-Based Case Report

Authors

  • Dono Antono Division of Cardiology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Ade Gautama Independent Scholar, Jakarta, Indonesia
  • Nindya P.B.S Utami Independent Scholar, Jakarta, Indonesia

Keywords:

ischemic, reperfusion injury, reperfusion, anti-inflammatory agents

Abstract

Background: Reperfusion serves as a mainstay therapy in almost all ischemic vascular diseases (IVD), but reperfusion may enhance cell damage after an ischemic period time. Increased ROS and inflammatory markers, decreasing organ function parameters, along with systemic inflammatory response and multi-organ damage may occur in ischemic reperfusion injury (IRI). Unfortunately, this series of events is unpredictable and sudden, causing high mortality in patients with IRI. Due to the significant role of inflammation in IRI, how is the effectiveness of anti-inflammatory agents administered before reperfusion therapy to prevent IRI? To know the efficacy of anti-inflammatory agents administered before reperfusion therapy to prevent IRI. Methods: A systematic search was conducted in databases (Pubmed, EMBASE, Scopus) and was later selected according to predetermined inclusion and exclusion criteria. Studies included later critically appraised using the CEBM Oxford questionnaire for randomized control trials and systematic review. Results: Seven studies were included among 1072 studies found in early searching. Six of the studies are randomized control trials, and one is a meta-analysis of randomized control trials. Methylprednisolone, pexelizumab, tirilazad mesylate, and N-acetylcysteine are known anti-inflammatory agents applicable in humans. The highest effectiveness of anti-inflammatory agents is methylprednisolone, with a relative risk reduction (RRR) of 75-85%. Besides that, pexelizumab also had an RRR of 27%, and tirilazad-mesylate had an RRR of 18%. N-acetylcysteine is not effective in preventing IRI. IL-6 levels postoperatively also decreased significantly in patients given anti-inflammatory agents before reperfusion therapy. There are no side effects of the intervention reported. Conclusion: Anti-inflammatory agent administration before reperfusion therapy effectively prevents IRI. The choices of anti-inflammatory agents recommended are methylprednisolone, pexelizumab, and tirilazad-mesylate. Anti-inflammatory agent administration before reperfusion therapy is recommended.

References

Saver JL, Smith EE, Fonarow GC, et al. The “golden hour” and acute brain ischemia: Presenting features and lytic therapy in > 30,000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41(7):1431–9.

Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 199. Vol. 110, Circulation. 2004. 588–636 p.

Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6):3S-125S.e40.

Ikhlas M, Atherton NS. Vascular reperfusion injury. StatPearls [Internet]. 2022;1–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32965881

Cowled P, Fitridge R. Pathophysiology of reperfusion injury. Mech Vasc Dis A Ref B Vasc Spec. 2011;331–50.

Xiao Y, Chen H, Liu D, et al. Comparação entre Dois Escores de Risco quanto à Predição de Obstrução Microvascular Coronariana durante a Intervenção Percutânea Primária. Arq Bras Cardiol. 2021;116(5):959–67.

Institute JB. Critical Appraisal Tools [Internet]. Joanna Briggs Institute. 2020. p. 12–3. Available from: https://jbi.global/critical-appraisal-tools

El-Hamamsy I, Stevens LM, Carrier M, et al. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: A randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg. 2007;133(1):7–12.

Volk T, Schmutzler M, Engelhardt L, et al. Effects of different steroid treatments on reperfusion-associated production of reactive oxygen species and arrhythmias during coronary surgery. Acta Anaesthesiol Scand. 2003;47(6):667–74.

Hasegawa Y, Nitta H, Takahara T, et al. Glucocorticoid use and ischemia-reperfusion injury in laparoscopic liver resection: Randomized controlled trial. Ann Gastroenterol Surg. 2020;4(1):76–83.

Aldrighetti L, Pulitano C, Aru M, et al. Impact of preoperative steroids administration on ischemia-reperfusion injury and systemic responses in liver surgery: A prospective randomized study. Liver Transplant. 2006;12:941–6.

Tohidinezhad F, Eslami S, Vakili S, Aliakbarian M, Tavakkoli M. Prevention of ischemia-reperfusion injury in human kidney transplantation: A meta-analysis of randomized controlled trials. Nephrourol Mon. 2020;12(2).

Pulitanò C, Aldrighetti L, Arru M, et al. Prospective randomized study of the benefits of preoperative corticosteroid administration on hepatic ischemia-reperfusion injury and cytokine response in patients undergoing hepatic resection. Hpb. 2007;9(3):183–9.

Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial. Jama. 2004;291(19):2319–27.

Ocejo A, Correa R. Methylprednisolone. 2022;1–8.

Sebba A. Tocilizumab: The first interleukin-6-receptor inhibitor. Am J Heal Pharm. 2008;65(15):1413–8.

Hall ED. Efficacy and mechanisms of action of the cytoprotective lipid peroxidation inhibitor tirilazad mesylate in subarachnoid hemorrhage. Eur J Anaesthesiol. 1996;13(3):279–89.

Elberry AA, Sharkawi SMZ, Wahba MR. Antinociceptive and anti-inflammatory effects of N-acetylcysteine and verapamil in Wistar rats. Korean J Pain. 2019;32(4):256–63.

Downloads

Published

2025-04-15

How to Cite

Antono, D., Gautama, A., & Utami, N. P. (2025). Anti-inflammatory Therapy Before Reperfusion Therapy in Patients with Ischemic Vascular Disease on the Incidence of Ischemic Reperfusion Injury: An Evidence-Based Case Report. Acta Medica Indonesiana, 57(1), 128. Retrieved from https://actamedindones.org/index.php/ijim/article/view/2434

Issue

Vol. 57 No. 1 (2025): Acta Medica Indonesiana

Section

SPECIAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.